Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and BMT with Optimized Donor Selection for B-cell Lymphomas
NCT00946023Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2009
- Primary completion
- Jul 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab in B cell lymphoma and chronic lymphocytic leukemia (CLL), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jul 2009; status: terminated.
02
Drugs
rituximab
03
Conditions
B cell lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00946023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00946023.